查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年神经系统生物标誌物的全球市场
市场调查报告书
商品编码
1270965

2023-2030 年神经系统生物标誌物的全球市场

Global Neurological Biomarker Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3个工作天内

价格

神经生物标誌物的全球市场规模、份额和趋势分析报告，按生物标誌物类型（成像生物标誌物、代谢组学生物标誌物、蛋白质组学生物标誌物、基因组学生物标誌物）、应用（阿尔茨海默病、帕金森病、多发病）、硬化症、自闭症谱系障碍等), 按最终用户（医院、临床诊断中心、研究机构）预测期（2023-2030）

在预测期内，全球神经生物标誌物市场预计将以 12.4% 的复合年增长率显着增长。 运动神经元病 (MND)、帕金森病 (PD)、中风、阿尔茨海默病 (AD)、亨廷顿舞蹈病 (HD) 等神经系统疾病以及肿瘤学、神经科学和心血管疾病 (CVD) 的患病率增加满足全球经济未满足需求的生物样本库将加速市场增长。 根据加拿大组织储存库网络 (CTRNet) 的数据，截至 2021 年 2 月，北美地区共有 278 个生物样本库。 此外，根据英国临床研究社区组织名录 (UKCRC-TD)，截至 2021 年 2 月，根据新南威尔士州健康病理学 (NSW-HP) 和英国的 274 家生物样本库，有 74 家生物样本库在增加。

此外，Fujirebio Diagnostics, Inc.、Thermo Fisher Scientific Inc. 和 Quanterix 等公司倾向于采用合作伙伴关係、协作和新产品发布等各种策略来推动市场增长，进一步推动市场增长。 例如，2023 年 3 月，Fujirebio Diagnostics, Inc. 和 AriBio Co, Ltd. 宣布建立战略合作伙伴关係，以推进阿尔茨海默病和其他神经退行性疾□□病生物标誌物的开发。 根据该协议，Fujirebio 将提供作为阿尔茨海默氏病 3 期试验的一部分收集的临床样本和数据。

细分市场展望

全球神经生物标誌物市场根据生物标誌物类型、应用和最终用户进行细分。 根据生物标誌物类型，市场分为成像生物标誌物、代谢组生物标誌物、蛋白质组生物标誌物和基因组生物标誌物。 根据应用，市场分为阿尔茨海默病、帕金森病、多发性硬化症、自闭症谱系障碍等。 基于最终用户，市场分为医院、临床诊断中心和研究机构。 在最终用户中，研究机构的子部分预计在未来几年将出现显着增长。 越来越多的研究人员参与识别血清和血浆中的关键生物标誌物，以及政府增加对研发中心的支出，预计将推动这一领域的增长。

预计帕金森病将占据全球神经生物标誌物市场的很大份额。

按生物标誌物类型划分，帕金森氏病子领域预计将在全球神经生物标誌物市场占据很大份额。 这是由于越来越多的帕金森病药物获得批准，以及公众对神经系统疾病的认识不断提高，这推动了这一领域的增长。 例如，2023 年 1 月，Neuroderm 公布了液体左旋多巴/卡比多巴 ND0612 的 III 期试验结果。 左旋多巴暂时替代大脑化学物质多巴胺，并以较低的每日剂量在较长时间内控制帕金森病的运动症状（震颤、缓慢和僵硬）。 它目前有片剂（口服）、吸入剂和凝胶（注射到小肠）的形式。 这种治疗适用于患有帕金森氏病且无法通过口服药物获得最佳症状控制的人。

区域展望

全球神经生物标誌物市场分为北美（美国、加拿大）、欧洲（英国、意大利、西班牙、德国、法国、欧洲其他地区）和亚太地区（印度、中国、日本、韩国、亚洲其他地区），以及世界其他地区（中东和非洲），按地区进一步细分。 北美地区预计将出现显着的市场增长。 客户越来越意识到使用生物标誌物诊断神经系统疾病、技术先进产品的可用性以及医疗保健基础设施的改善是推动该地区市场增长的一些关键因素。已成为一个部门。

北美主导着全球神经生物标誌物市场

北美预计将在神经生物标誌物市场占据显着的市场份额。 这种高增长归因于神经系统疾病患病率的上升和临床试验数量的增加。 例如，根据阿尔茨海默氏症协会的数据，到 2023 年，将有近 670 万 65 岁及以上的美国人患有阿尔茨海默氏病，其中 73% 的年龄在 75 岁及以上。 在 65 岁以上的老人中，大约每 9 人中就有 1 人患有阿尔茨海默病，据说患有阿尔茨海默病的美国人中约有三分之二是女性。 FDA 对神经疾病的批准不断增加也是推动市场增长的因素之一。 例如，2022年12月，美国FDA批准了霍夫曼罗氏公司开发的两款新药Elecsys Phospho-Tau (181P) CSF (pTau181)和Elecsys beta-Amyloid (1-42) CSF II (Abeta42) . 我们有两种免疫测定在美国获得批准。 这两种测定法测量成年患者的两种重要生物标誌物，tau 蛋白和 β-淀粉样蛋白，以确认阿尔茨海默氏病的诊断。

市场参与者展望

全球神经生物标誌物市场的主要参与者包括 Abbott Laboratories、Bio-Rad Laboratories Inc.、Qiagen N.V.、Quanterix 和 Thermo Fisher Inc。 市场参与者通过采用併购、地域扩张、合作伙伴关係、产品发布和竞争等各种战略来保持市场竞争力，为市场增长做出了重大贡献。 例如，2020 年 9 月，美国国立卫生研究院 (NIH) 向北德克萨斯大学健康科学中心授予 4550 万美元的研究经费，用于开发更多的生物标誌物。 这笔资金将用于了解墨西哥裔美国人和非拉丁裔白种人大脑老化的病理学。

本报告涵盖：

  • 2022 年市场价值数据分析和到 2030 年的预测
  • 每个细分市场的年度市场销售额
  • 主要地区的国家分析
  • 在全球神经生物标誌物市场运营的领先企业。 根据数据可用性，与新产品发布和相关新闻相关的信息也将包含在报告中。
  • 通过确定未来强劲增长的关键细分市场来分析业务战略
  • 市场进入和市场扩张战略分析
  • 通过识别市场中的“谁站在哪里”来製定竞争策略

内容

第 1 章报告概述

  • 分析行业现状和发展前景
  • 研究方法和工具
  • 市场细分
    • 按细分
    • 按地区

第 2 章市场概述和洞察

  • 调查范围
  • 分析师观点和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第三章竞争格局

  • 主要公司分析
  • 雅培实验室
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期趋势
  • Bio-Rad 实验室公司
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期发展状况
  • Qiagen N.V.
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期发展状况
  • Quanterix 公司
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期发展状况
  • Thermo Fisher Scientific Inc.
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期发展状况
  • 关键策略分析

第四章市场细分

  • 全球神经系统生物标誌物市场：按生物标誌物类型分类
    • 成像生物标誌物
    • 代谢组学生物标誌物
    • 蛋白质组学生物标誌物
    • 基因组学生物标誌物
  • 按应用划分的全球神经系统生物标誌物市场
    • 阿尔茨海默氏痴呆症
    • 帕金森病 多发性硬化症）
    • 自闭症谱系
    • 其他（中风、癫痫等）
  • 全球神经系统生物标誌物市场：按最终用户分类
    • 医院
    • 临床诊断中心
    • 研究所

按地区分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 世界其他地区

第二章公司简介

  • Advanced Brain Monitoring, Inc.
  • AnaSpec
  • Athena Diagnostics, Inc.
  • BioMerieux, Inc.
  • C2N's Diagnostics
  • Enzo Life Sciences, Inc.,
  • Fujirebio Europe N.V
  • Imagilys
  • Labcorp
  • NanoSomiX, Inc
  • Neurosteer Ltd.
  • Proteome Sciences PLC
  • Psynova Neurotech Ltd.
  • Roche Diagnostics
Product Code: OMR2027234

Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Biomarker Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers), by Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), and by End Users (Hospital, Clinical Diagnostic Centers, Research Organizations) Forecast Period (2023-2030)

The global neurological biomarkers market is anticipated to grow at a significant CAGR of 12.4% during the forecast period. The increase in the prevalence of neurological diseases such as motor neuron disease (MND), Parkinson's disease (PD), stroke, Alzheimer's disease (AD), and Huntington's disease (HD), and the increase in biobanks for addressing unmet requirements in oncology, neuroscience, and cardiovascular disease (CVDs) to accelerate the market growth. According to the Canadian Tissue Repository Network (CTRNet), there are 278 biobanks in the North American region as of February 2021. Furthermore, according to the New South Wales Health Pathology (NSW-HP), there are 74 biobanks, and there are 274 biobanks in the UK as of February 2021, according to the UKCRC-TD, the UK Clinical Research Collaboration Tissue Directory.

In addition, companies including Fujirebio Diagnostics, Inc., Thermo Fisher Scientific Inc., Quanterix, and others are inclined towards adopting various strategies such as partnership, collaboration, and new product launches, that further drive market growth. For instance, in March 2023, Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer's disease and other neurodegenerative conditions. The agreement provides Fujirebio access to clinical samples and data collected as part of the Phase 3 Alzheimer's disease study.

Segmental Outlook: 

The global neurological biomarkers market is segmented based on biomarker type, application, and end user. Based on biomarker type, the market is sub-segmented into imaging biomarkers, metabolomics biomarkers, proteomic biomarkers, and genomics biomarkers. Based on the application, the market is sub-segmented into Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Autism Spectrum Disorders, and others. Based on end user, the market is categorized into hospitals, clinical diagnostic centers, research organization. Among the end users, the research organization sub-segment is anticipated to grow at a significant rate in the coming years. An increasing number of researchers are involved in identifying key biomarkers in serum and plasma, and rising government expenditure for R&D centers to drive the segment growth.

The Parkinson's Disease Sub-Segment is Anticipated to Hold a Considerable Share of the Global Neurological Biomarkers Market

Among the biomarker type, the Parkinson's disease sub-segment to holds a prominent share of the global neurological biomarkers market. The growth is mainly attributed owing to the rising number of drug approval for the treatment of Parkinson's disease, coupled with increasing awareness among the people regarding the neurological diseases, drive the segment's growth. For instance, in January 2023, Neuroderm announced results from its Phase III trial on ND0612, a liquid levodopa/carbidopa. Levodopa temporarily replaces the dopamine brain chemical, and control Parkinson's motor symptoms (tremor, slowness, stiffness) for longer periods of time and with fewer doses each day. It's currently available as a pill (to take by mouth), inhaler or gel (for infusion into the small intestine). This treatment is for those people who are suffered form Parkinson's and are unable to achieve optimal symptom control with oral medications.

Regional Outlooks:

The global neurological biomarkers market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. The North American region is anticipated to witness considerable growth in the market. The rise in customer awareness about the use of biomarkers in diagnosing neurological disorders, the availability of technologically advanced products, and improved healthcare infrastructure, are some of the major factors that drive the market growth in the region.

The North America Region to Hold a Prominent Share of the Global Neurological Biomarkers Market

The North American region is projected to hold a prominent market share in the neurological biomarker market. This high growth is attributed to the rising prevalence of neurological diseases and the increasing number of clinical trials. For instance, according to the Alzheimer Association, nearly 6.7 million Americans age 65 and older are living with Alzheimer's in 2023, and 73% are aged 75 years and above. About 1 in 9 people aged 65 and older has Alzheimer's, and almost two-thirds of Americans with Alzheimer's are women. In addition, rising FDA approval for neurological disorder diseases is another factor that boosts market growth. For instance, in December 2022, the US FDA approved two immunoassays, Elecsys Phospho-Tau (181P) CSF (pTau181) and Elecsys beta-Amyloid (1-42) CSF II (Abeta42), developed by F. Hoffmann-La Roche Ltd. in the US. These two assays measure two important biomarkers-tau proteins and beta-amyloid-in adult patients to confirm the diagnosis of Alzheimer's disease.

Market Players Outlook:

The major companies serving the global neurological biomarkers market include Abbott Laboratories, Bio-Rad Laboratories Inc., Qiagen N.V., Quanterix, Thermo Fisher Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, geographical expansions, partnerships, product launches, and collaborations, to stay competitive in the market. For instance, in September 2020, the National Institutes of Health (NIH) granted research funding of $45.5 million to the University of North Texas Health Science Center for developing additional biomarkers. This funding is used for understanding the pathology of brain aging in Mexican Americans and non-Latino Whites populations.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global neurological biomarkers market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1.Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1.Research Methods and Tools
  • 1.2.Market Breakdown
    • 1.2.1.By Segments
    • 1.2.2.ByRegion

2.Market Overview and Insights

  • 2.1.Scope of the Report
  • 2.2.Analyst Insight and Current Market Trends
    • 2.2.1.Key Findings
    • 2.2.2.Recommendations
    • 2.2.3.Conclusion

3.Competitive Landscape

  • 1.1.Key Company Analysis
  • 3.1. Abbott Laboratories
    • 3.1.1.Overview
    • 3.1.2.Financial Analysis
    • 3.1.3.SWOT Analysis
    • 3.1.4.Recent Developments
  • 3.2.Bio-Rad Laboratories Inc. 
    • 3.2.1.Overview
    • 3.2.2.Financial Analysis
    • 3.2.3.SWOT Analysis
    • 3.2.4.Recent Developments
  • 3.3.Qiagen N.V.
    • 3.3.1.Overview
    • 3.3.2.Financial Analysis
    • 3.3.3.SWOT Analysis
    • 3.3.4.Recent Developments
  • 3.4.Quanterix Corp. 
    • 3.4.1.Overview
    • 3.4.2.Financial Analysis
    • 3.4.3.SWOT Analysis
    • 3.4.4.Recent Developments
  • 3.5.Thermo Fisher Scientific Inc.
    • 3.5.1.Overview
    • 3.5.2.Financial Analysis
    • 3.5.3.SWOT Analysis
    • 3.5.4.Recent Developments
  • 3.6.Key Strategy Analysis

4.Market Segmentation

  • 4.1.Global Neurological Biomarkers Market by Biomarker Type
    • 4.1.1.Imaging Biomarkers
    • 4.1.2.Metabolomics Biomarkers
    • 4.1.3.Proteomic Biomarkers
    • 4.1.4.Genomics Biomarkers
  • 4.2.Global Neurological Biomarkers Market by Application
    • 4.2.1.Alzheimer's Disease
    • 4.2.2.Parkinson's Disease
    • 4.2.3.Multiple Sclerosis
    • 4.2.4.Autism Spectrum Disorders
    • 4.2.5.Others (stroke, or epilepsy)
  • 4.3.Global Neurological Biomarkers Market by End User
    • 4.3.1.Hospital
    • 4.3.2.Clinical Diagnostic Centers
    • 4.3.3.Research Organizations

Regional Analysis

  • 1.2.North America
    • 1.2.1.US
    • 1.2.2.Canada
  • 1.3.Europe
    • 1.3.1.UK
    • 1.3.2.Germany
    • 1.3.3.Italy
    • 1.3.4.Spain
    • 1.3.5.France
    • 1.3.6.Rest of Europe
  • 1.4.Asia-Pacific
    • 1.4.1.China
    • 1.4.2.India
    • 1.4.3.Japan
    • 1.4.4.South Korea
    • 1.4.5.Rest of Asia-Pacific
  • 1.5.Rest of the World

2.Company Profiles

  • 2.1.Advanced Brain Monitoring, Inc. 
  • 2.2.AnaSpec 
  • 2.3.Athena Diagnostics, Inc.
  • 2.4.BioMerieux, Inc.
  • 2.5.C2N's Diagnostics
  • 2.6.Enzo Life Sciences, Inc.,
  • 2.7.Fujirebio Europe N.V
  • 2.8.Imagilys
  • 2.9.Labcorp 
  • 2.10.NanoSomiX, Inc
  • 2.11.Neurosteer Ltd.
  • 2.12.Proteome Sciences PLC
  • 2.13.Psynova Neurotech Ltd.
  • 2.14.Roche Diagnostics

LIST OF TABLES

  • 1.GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 2.GLOBAL IMAGING BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3.GLOBAL METABOLOMICS BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4.GLOBAL PROTEOMIC BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5.GLOBAL GENOMICS BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6.GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 7.GLOBAL NEUROLOGICAL BIOMARKERS FOR ALZHEIMER'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8.GLOBAL NEUROLOGICAL BIOMARKERS FOR PARKINSON'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9.GLOBAL NEUROLOGICAL BIOMARKERS FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10.GLOBAL NEUROLOGICAL BIOMARKERS FOR AUTISM SPECTRUM DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11.GLOBAL NEUROLOGICAL BIOMARKERS FOR OTHER (STROKE, OR EPILEPSY) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)

GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

  • 13.GLOBAL NEUROLOGICAL BIOMARKERS IN HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14.GLOBAL NEUROLOGICAL BIOMARKERS IN CLINICAL DIAGNOSTICS CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15.GLOBAL NEUROLOGICAL BIOMARKERS IN RESEARCH ORGANIZATION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)

GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)

  • 17.NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18.NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 19.NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 20.NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 21.EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 22.EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 23.EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 24.EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25.ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26.ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 27.ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 28.ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 29.REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 30.REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
  • 31.REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 32.REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1.GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY BIOLOGICAL TYPE, 2022 VS 2030 (%)
  • 2.GLOBAL IMAGING BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3.GLOBAL METABOLOMICS BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4.GLOBAL PROTEOMIC BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5.GLOBAL GENOMICS BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6.GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 7.GLOBAL NEUROLOGICAL BIOMARKERS FOR ALZHEIMER'S DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8.GLOBAL NEUROLOGICAL BIOMARKERS FOR PARKINSON'S DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9.GLOBAL NEUROLOGICAL BIOMARKERS FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10.GLOBAL NEUROLOGICAL BIOMARKERS FOR AUTISM SPECTRUM DISORDERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11.GLOBAL NEUROLOGICAL BIOMARKERS FOR OTHERS (STROKE OR EPILEPSY) MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12.GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 13.GLOBAL NEUROLOGICAL BIOMARKERS IN HOSPITAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14.GLOBAL NEUROLOGICAL BIOMARKERS IN CLINICAL DIAGNOSTICS CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15.GLOBAL NEUROLOGICAL BIOMARKERS IN RESEARCH ORGANIZATION MARKET SHARE BY REGION, 2022 VS 2030 (%)

GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)

  • 17.US NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18.CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19.UK NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20.FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21.GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22.ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23.SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24.REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25.INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26.CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27.JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28.SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29.REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)

REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)